Novo Nordisk's hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...

Both results wiped significant value from Novo's share price as investors' hopes of finding a superior alternative to the company's existing Wegovy injection and rival Eli Lily's Zebound ...

Novo Nordisk's hopes of heralding a new era of obesity treatment with its CagriSema drug have been called into question after a series of trial results sent shares falling. Headline results from a ...